Treatment
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 program1
Parent assisted social skills trainingPhase 1/21 trial
Active Trials
UNION therapeuticsDenmark - Hellerup
1 program1
liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatinPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
UNION therapeuticsliposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
Puhe BiopharmaYK-029A
Angeles TherapeuticsParent assisted social skills training
Clinical Trials (3)
Total enrollment: 160 patients across 3 trials
NCT05441761UNION therapeuticsliposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
Start: May 2022Est. completion: May 202560 patients
Phase 1/2Unknown
Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR
Start: Mar 2018Est. completion: May 2024
Phase 1/2Unknown
Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships
Start: Oct 2001Est. completion: Jan 2005100 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.